Patrys CEO and MD, Dr James Campbell, was interviewed by Andrew Scott from Proactive about new preclinical data for its full-sized IgG antibody, PAT-DX3, showing that it can cross the blood-brain barrier in healthy animals.

"These properties open up a range of applications for using deoxymabs to deliver small molecule therapeutics and gene editing technologies directed to various neurological targets and conditions," said Dr Campbell.

Watch the interview here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Patrys Limited published this content on 17 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 November 2022 00:16:04 UTC.